Results 261 to 270 of about 103,481 (331)

Prenatal alcohol exposure increases the aggressiveness of estrogen‐induced pituitary tumors in male rats

Alcohol, Clinical and Experimental Research, EarlyView.
Prenatal alcohol exposure (PAE) enhances the development of aggressive pituitary tumors (PitNETs) in female rats. In this study, we found that PAE also promotes the development of PitNETs in male rats. Like in females, PAE treatment enhances the expression of stem cell and tumor aggressiveness genes and increases tumor cell proliferation rate ...
Shaista Chaudhary, Dipak K. Sarkar
wiley   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.

JAMA Neurol, 2022
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE, PD MED Collaborative Group.   +12 more
europepmc   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Conclusion lessons from the novel D2 dopamine receptor, β2-adrenoceptor agonist, Viozan™: chronic obstructive pulmonary disease and drug development implications

, 2003
P. M. A. Calverley, E.T. Keating, Mitch Goldman, Frank E. Casty   +3 more
openalex   +1 more source

An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications

The American Journal on Addictions, EarlyView.
Abstract Background Opioid use disorder (OUD) imposes a significant socioeconomic burden, highlighting the need for new interventions. Objective This study investigated whether exposure to 5‐alpha reductase inhibitors (5αRIs) is associated with a lower risk of developing OUD.
Abdelrahman G. Tawfik, Tyler Lister, Ainhoa Gomez‐Lumbreras, Randall T. Peterson, Marco Bortolato, Daniel C. Malone   +5 more
wiley   +1 more source

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

Andrology, EarlyView.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret, Aaran H. Patel, Elisabeth Daniels, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Early clinical investigation of Viozan™ (sibenadet HCI), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms

, 2003
P.W. Ind, L. A. Laitinen, L. Laursen, Sally E. Wenzel, E.F.M. Wouters, L. Deamer, P O Nyström   +6 more
openalex   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Conclusion lessons from the novel D2 dopamine receptor, $beta;2-adrenoceptor agonist, Viozan?: chronic obstructive pulmonary disease and drug development implications

, 2003
P CALVERLEY
openalex   +1 more source